Related Experiment Video

Updated: Oct 19, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

575

Risk factors for hypertension in primary Sjögren's syndrome patients: a nomogram was constructed

Xueping Xu1,2, Yong Shi3, Xiaoqian Yang1,2

  • 1Department of Cardiology, The Affiliated Hospital of Southwest Jiaotong University/The Third People's Hospital of Chengdu, Chengdu, China.

Journal of Human Hypertension
|September 25, 2021
PubMed

Insights

Hypertension is common in primary Sjögren's syndrome (pSS) patients. Key risk factors identified include age, pSS duration, LDL-c, and anti-SSA antibodies, enabling early detection and prevention.

Area of Science:

  • Rheumatology
  • Cardiology
  • Internal Medicine

Background:

  • Cardiovascular disease (CVD) is a leading cause of mortality in primary Sjögren's syndrome (pSS).
  • Hypertension is a significant independent risk factor for CVD in pSS patients, with higher prevalence than in the general population.

Purpose of the Study:

  • To identify risk factors for hypertension in patients with primary Sjögren's syndrome (pSS).
  • To develop a predictive model for hypertension risk in the pSS population.

Main Methods:

  • A retrospective study involving 488 pSS patients from two hospitals.
  • Multiple logistic regression analysis was employed to screen for risk factors.
  • A nomogram was constructed based on significant risk factors and validated for discrimination and calibration.

Main Results:

  • Patients with hypertension were older, had longer pSS duration, higher LDL-c, and positive anti-SSA antibodies.
  • Other associated factors included smoking, xerophthalmia, xerostomia, and use of certain medications.
  • The developed nomogram demonstrated good predictive accuracy (C-index 0.812) and calibration.

Conclusions:

  • Age, pSS duration, LDL-c, and anti-SSA antibody status are significant predictors of hypertension in pSS.
  • The validated nomogram can aid clinicians in early hypertension detection and preventive strategies for pSS patients.

More Related Videos

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research07:25

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

3.5K
Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients05:26

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

1.4K

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
107
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
181
Factors affecting Blood pressure01:28

Factors affecting Blood pressure

Several physiological and lifestyle factors influence blood pressure (BP). Understanding these factors is crucial as they are significant in patient education and blood pressure management.
Physiological Factors:
5.5K
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
176
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.3K
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
148